basskilleronline steroid articles
Egg Whites International
Basskilleronline Menu
Main Page
Anti-estrogen Articles
Antioxidants Articles
Bodybuilding Articles
Bodybuilding DVD's
Cardio Articles
Steroid Conversion Articles
Competition Articles
fatloss Articles
Steroid Profiles
Finaplix Articles
Fitness Articles
Hcg diet, does it work
Health Articles
HGH Articles
IGF-1 Articles
Insulin Articles
Building Muscle Articles
Bodybuilding Message Boards
bodybuilding peptides
Post Cycle Therapy Articles
Powerlifting Articles
Fitness and Diet Recipes
Research Sites
Selective androgen receptor modulator
Sponsors Steroid Articles
Supplement Articles
Women's Fitness Articles
Workout Routines

Anavar aids fatloss

Anavar and Fat burning

Int J Obes Relat Metab Disord 1995 Sep;19(9):614-24

Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.

Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.

OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means.

DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL).

MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters.

RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters.

CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat.


Anavar at 15mg

Short-term oxandrolone administration stimulates net muscle protein synthesis in young men.

Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, Wolfe RR, Ferrando AA.

Department of Surgery, University of Texas Medical Branch, and Shriners Burn Hospital for Children, Galveston 77550, USA.

Short term administration of testosterone stimulates net protein synthesis in healthy men. We investigated whether oxandrolone [Oxandrin (OX)], a synthetic analog of testosterone, would improve net muscle protein synthesis and transport of amino acids across the leg. Six healthy men [22+/-1 (+/-SE) yr] were studied in the postabsorptive state before and after 5 days of oral OX (15 mg/day). Muscle protein synthesis and breakdown were determined by a three-compartment model using stable isotopic data obtained from femoral arterio-venous sampling and muscle biopsy. The precursor-product method was used to determine muscle protein fractional synthetic rates. Fractional breakdown rates were also directly calculated. Total messenger ribonucleic acid (mRNA) concentrations of skeletal muscle insulin-like growth factor I and androgen receptor (AR) were determined using RT-PCR. Model-derived muscle protein synthesis increased from 53.5+/-3 to 68.3+/-5 (mean+/-SE) nmol/min.100 mL/leg (P < 0.05), whereas protein breakdown was unchanged. Inward transport of amino acids remained unchanged with OX, whereas outward transport decreased (P < 0.05). The fractional synthetic rate increased 44% (P < 0.05) after OX administration, with no change in fractional breakdown rate. Therefore, the net balance between synthesis and breakdown became more positive with both methodologies (P < 0.05) and was not different from zero. Further, RT-PCR showed that OX administration significantly increased mRNA concentrations of skeletal muscle AR without changing insulin-like growth factor I mRNA concentrations. We conclude that short term OX administration stimulated an increase in skeletal muscle protein synthesis and improved intracellular reutilization of amino acids. The mechanism for this stimulation may be related to an OX-induced increase in AR expression in skeletal muscle.


Anavar at 15mg with high protien diet.

Combined effects of hyperaminoacidemia and oxandrolone on skeletal muscle protein synthesis.

Sheffield-Moore M, Wolfe RR, Gore DC, Wolf SE, Ferrer DM, Ferrando AA.

Department of Surgery, University of Texas Medical Branch, Galveston 77550, USA.

We investigated whether the normal anabolic effects of acute hyperaminoacidemia were maintained after 5 days of oxandrolone (Oxandrin, Ox)-induced anabolism. Five healthy men [22 +/- 3 (SD) yr] were studied before and after 5 days of oral Ox (15 mg/day). In each study, a 5-h basal period was followed by a 3-h primed-continuous infusion of a commercial amino acid mixture (10% Travasol). Stable isotopic data from blood and muscle sampling were analyzed using a three-compartment model to calculate muscle protein synthesis and breakdown. Model-derived muscle protein synthesis increased after amino acid infusion in both the control [basal control (BC) vs. control + amino acids (C+AA); P < 0.001] and Ox study [basal Ox (BOx) vs. Ox + amino acids (Ox+AA); P < 0.01], whereas protein breakdown was unchanged. Fractional synthetic rates of muscle protein increased 94% (BC vs. C+AA; P = 0.01) and 53% (BOx vs. Ox+AA; P < 0.01), respectively. We conclude that the normal anabolic effects of acute hyperaminoacidemia are maintained in skeletal muscle undergoing oxandrolone-induced anabolism.


Treatment with Oxandrolone and the Durability of Effects in Older Men.

Schroeder ET, Zheng L, Yarasheski KE, Qian D, Stewart Y, Flores C, Martinez C, Terk M, Sattler FR.

Division of Infectious Diseases, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA; Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, CA, USA.

We investigated the effects of the anabolic androgen, oxandrolone, on lean body mass (LBM), muscle size, fat, and maximum voluntary muscle strength, and determined the durability of effects after stopping treatment. Thirty-two healthy 60-87 year old men were randomized to receive 20 mg oxandrolone/day (n = 20) or placebo (n = 12) for 12 weeks. Body composition (DEXA, MRI and D2O dilution) and muscle strength (1-repetition maximum; 1-RM) were evaluated at baseline and after 12 weeks of treatment; body composition (DEXA) and 1-RM strength were then assessed 12 week after discontinuing treatment (week 24). At week 12, oxandrolone increased LBM 3.0+/-1.5kg (P<0.001), total body water 2.9+/-3.7kg (P=0.002), proximal thigh muscle area 12.4+/-8.4cm(2) (P<0.001); these increases were greater (P<0.003) than in the placebo group. Oxandrolone increased 1-RM strength for leg press 6.7+/-6.4% (P<0.001), leg flexion 7.0+/-7.8% (P<0.001), chest press 9.3+/-6.7% (P<0.001), and latissimus pull-down 5.1+/-9.1% (P=0.02) exercises; these increases were greater than placebo. Oxandrolone reduced total (-1.9+/-1.0kg) and trunk fat (-1.3 +/-0.6kg; P<0.001) and these decreases were greater (P<0.001) than placebo. Twelve weeks after discontinuing oxandrolone (week 24), the increments in LBM and muscle strength were no longer different from baseline (P>0.15). However, the decreases in total and trunk fat were sustained (-1.5+/-1.8, P=0.001 and -1.0+/-1.1kg, P<0.001, respectively). Thus, oxandrolone induced short-term improvements in lean body mass, muscle area, and strength, while reducing whole-body and trunk adiposity. Anabolic improvements were lost 12 weeks after discontinuing oxandrolone, while improvements in fat mass were largely sustained.

Books and Courses

Great Websites

Excellent Stores

Recipe Cook Books

eXTReMe Tracker